Organicell Regenerative Medicine, Inc. OCEL
We take great care to ensure that the data presented and summarized in this overview for Organicell Regenerative Medicine, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OCEL
Top Purchases
Top Sells
About OCEL
Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.
Insider Transactions at OCEL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 20
2024
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
7,289
+2.44%
|
$14,578
$2.75 P/Share
|
|
Nov 19
2024
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
5,000
+1.73%
|
$10,000
$2.65 P/Share
|
|
Nov 18
2024
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
10,000
+3.47%
|
$20,000
$2.59 P/Share
|
|
Sep 03
2024
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
9,000
+3.24%
|
$18,000
$2.2 P/Share
|
|
Aug 30
2024
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,000
+0.38%
|
$2,000
$2.2 P/Share
|
|
Apr 01
2024
|
Steven Jerry Glauser Director |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+32.61%
|
-
|
|
Apr 01
2024
|
Leathem S Stearn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
62,500
+33.33%
|
-
|
|
Dec 19
2023
|
Harry L. Leider Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
5,248
-100.0%
|
$5,248
$1.31 P/Share
|
|
Jul 07
2023
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
320,710
+0.62%
|
$0
$0.01 P/Share
|
|
Jun 29
2023
|
Harry L. Leider Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
500,000
+32.27%
|
$0
$0.01 P/Share
|
|
Jun 29
2023
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+0.39%
|
$0
$0.01 P/Share
|
|
Jun 28
2023
|
Harry L. Leider Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
549,450
+50.0%
|
$0
$0.1 P/Share
|
|
Jun 28
2023
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
400,000
+0.78%
|
$0
$0.01 P/Share
|
|
Jun 26
2023
|
Skycrest Holdings, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,000
+1.55%
|
$0
$0.01 P/Share
|
|
Oct 31
2022
|
Matthew Phillip Sinnreich President and Acting CEO |
SELL
Other acquisition or disposition
|
Indirect |
6,979
-100.0%
|
-
|
|
Oct 13
2022
|
Matthew Phillip Sinnreich President and Acting CEO |
SELL
Open market or private sale
|
Indirect |
20,000
-0.29%
|
$0
$0.04 P/Share
|
|
Oct 29
2021
|
Ian T Bothwell Interim CEO & CFO |
BUY
Other acquisition or disposition
|
Direct |
15,000,000
+9.2%
|
-
|
|
Oct 29
2021
|
Ian T Bothwell Interim CEO & CFO |
SELL
Other acquisition or disposition
|
Direct |
15,000,000
-10.13%
|
-
|
|
Oct 29
2021
|
George Craig Shapiro Chief Medical Officer |
BUY
Other acquisition or disposition
|
Direct |
5,000,000
+5.84%
|
-
|
|
Oct 29
2021
|
George Craig Shapiro Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
5,000,000
-6.2%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 32.3K shares |
|---|---|
| Grant, award, or other acquisition | 188K shares |
| Open market or private sale | 5.25K shares |
|---|